Lung Cancer Immunotherapy: Improving Patient Outcomes Across the Disease Continuum

Join us in person or online for this live symposium at SITC 2022 Annual Meeting to hear expert insights on best practices for the use of immune checkpoint inhibitor therapy for patients with NSCLC.

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Clinical Care Options, LLC. is committed to providing a safe and healthy environment for all our learners. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. In addition, in accordance with The Society for Immunotherapy of Cancer’s (SITC) COVID-19 protocols, all in-person learners will be asked to wear a mask and present their SITC conference badge -OR- proof of vaccination* AND government-issued ID to gain admittance to Lung Cancer Immunotherapy: Improving Patient Outcomes Across the Disease Continuum.

For more information on SITC’s vaccination and mask requirements, please visit: SITC ‘s website.

*If you do not have your vaccination record card, find other ways to verify you have been vaccinated.

The Lung Cancer Immunotherapy: Improving Patient Outcomes Across the Disease Continuum, content and views expressed therein are those of Clinical Care Options, LLC and not of SITC.

Agenda

7:30 PM Welcome and Introduction

7:35 PM Overview of Immunotherapy in Nonmetastatic NSCLC

8:00 PM Evolving Role of Immunotherapy in Advanced or Metastatic NSCLC

8:25 PM Immunotherapy for Special Populations and Future Directions

8:50 PM Final Panel Discussion and Audience Question and Answer Session

Events

Date / Time
Event Details

Faculty

Program Director
Julie R. Brahmer, MD

Professor of Oncology
Upper Aerodigestive Cancer Program
Department of Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Faculty
Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Faculty
Zofia Piotrowska, MD

Assistant Professor
Harvard Medical School
Attending Physician
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in integrating immunotherapies into treatment plans for patients with NSCLC.

Target Audience
This educational program is intended to reach oncologists and other healthcare professionals working in the field of cancer immunotherapy involved in the care of patients with lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select optimal immune checkpoint inhibitor–based therapy for appropriate patients with NSCLC in the adjuvant and neoadjuvant settings, considering PD-L1 expression and expert recommendations
  • Evaluate the impact of immune checkpoint inhibitor treatment in the neoadjuvant and adjuvant settings on agent sequencing and treatment decisions for patients with advanced or metastatic NSCLC
  • Identify patients most likely to benefit from immunotherapy for unresectable stage III NSCLC following chemoradiation therapy
  • Incorporate investigational checkpoint inhibitors and clinical trial participation as part of therapeutic strategies for all eligible patients with NSCLC, considering known racial-related and age-related disparities in care
  • Address factors that can influence response to immune checkpoint inhibitor therapy in individual patients with NSCLC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.